Blockchain could change patient health records

Giving patients more control over their medical records is a goal of CMS, but the capability to engage patients in their own data goes even further with blockchain technology.

Blockchain technology, which is a digital ledger that records information about transactions, is already expected to have a major impact in the healthcare space, and the wearables sector, patient records and clinical trials could do with an injection of the technology, as well, writes Lucas Mearian for ComputerWorld.

In addition to typical health information, patients who use wearables and other tracking technology could consent to providing more information, such as exercise, sleep and diet data, that could give physicians more insight into overall health. Blockchain could help secure all this data, giving patients more control and engagement in their personal health record.

In its building blocks, blockchain technology is also a more secure platform for clinical trials, as the data is immutable and creates a trail for oversight.

A blockchain network of health information could also solve one of the biggest problems with EHRs. When they were built across proprietary softwares from different vendors and for different healthcare provides, EHRs continued to grow without being able to easily share information between providers or seamlessly integrate new data from new sources. This set up leaves valuable data unused and siloed. 

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.